Dumont & Blake Investment Advisors LLC Sells 1,507 Shares of GSK plc (NYSE:GSK)

Dumont & Blake Investment Advisors LLC trimmed its holdings in shares of GSK plc (NYSE:GSK) by 11.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,111 shares of the pharmaceutical company’s stock after selling 1,507 shares during the quarter. Dumont & Blake Investment Advisors LLC’s holdings in GSK were worth $410,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in GSK. AQR Capital Management LLC boosted its position in shares of GSK by 103.4% in the second quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock worth $1,015,000 after purchasing an additional 13,403 shares during the period. Creative Planning boosted its position in shares of GSK by 4.8% in the second quarter. Creative Planning now owns 203,246 shares of the pharmaceutical company’s stock worth $7,825,000 after purchasing an additional 9,322 shares during the period. NewEdge Advisors LLC boosted its position in shares of GSK by 61.9% in the second quarter. NewEdge Advisors LLC now owns 70,048 shares of the pharmaceutical company’s stock worth $2,697,000 after purchasing an additional 26,793 shares during the period. Sanctuary Advisors LLC bought a new position in shares of GSK in the second quarter worth approximately $11,181,000. Finally, Newbridge Financial Services Group Inc. boosted its position in shares of GSK by 172.2% during the second quarter. Newbridge Financial Services Group Inc. now owns 3,103 shares of the pharmaceutical company’s stock worth $119,000 after acquiring an additional 1,963 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GSK. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Trading Up 0.8 %

GSK opened at $35.35 on Friday. The firm has a market cap of $73.27 billion, a P/E ratio of 22.96, a P/E/G ratio of 1.37 and a beta of 0.63. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a 50-day moving average of $34.01 and a 200 day moving average of $37.73.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.